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Abstract
Background: We aimed to characterize changes in patterns of new HIV diagnoses, HIV-related mortality, and HAART use in
Canada from 1995 to 2008.
Methods: Data on new HIV diagnoses were obtained from Health Canada, HIV-related mortality statistics were obtained
from Statistics Canada, and information on the number of people on HAART was obtained from the single antiretroviral
distribution site in British Columbia (BC), and the Intercontinental Marketing Services Health for Ontario and Quebec. Trends
of new HIV-positive tests were assessed using Spearman rank correlations and the association between the number of
individuals on HAART and new HIV diagnoses were estimated using generalized estimating equations (GEE).
Results: A total of 34,502 new HIV diagnoses were observed. Rates of death in BC are higher than those in Ontario and
Quebec with the rate being 2.03 versus 1.06 and 1.21 per 100,000 population, respectively. The number of HIV infected
individuals on HAART increased from 5,091 in 1996 to 20,481 in 2008 in the three provinces (4 fold increase). BC was the
only province with a statistically significant decrease (trend test p,0.0001) in the rate of new HIV diagnoses from 18.05 to
7.94 new diagnoses per 100,000 population. Our analysis showed that for each 10% increment in HAART coverage the rate
of new HIV diagnoses decreased by 8% (95% CI: 2.4%, 13.3%)
Interpretation: Except for British Columbia, the number of new HIV diagnoses per year has remained relatively stable across
Canada over the study period. The decline in the rate of new HIV diagnoses per year may be in part attributed to the greater
expansion of HAART coverage in this province.
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Introduction
Every year 3,300 men and women in Canada are diagnosed
with HIV infection. Extrapolating from national estimates, 65,000
Canadians are now living with HIV [1] and based on this 2008
estimate and the current rate of new infections this number could
double within the next 15 years.
Canadians living with HIV come from all facets of society and
from all regions [1–6]. Nearly half of these infections (48%) are
among men who have sex with men. Other groups disproportion-
ally affected by HIV in Canada include injection drug users
(IDUs), Aboriginal Peoples, and migrants from endemic countries.
Though, most Canadians living with HIV reside in Ontario,
Quebec and British Columbia, the fastest growing epidemic in
Canada is in Saskatchewan where on average 200 new people are
diagnosed with HIV infection each year [7].
Untreated HIV infection leads to progressive immune system
failure, which in turn leads to the development of opportunistic
infections and cancers that ultimately lead to death within 10 to 15
years [8]. Since 1996, with the advent of highly active
antiretroviral therapy (HAART) HIV disease has become a
chronic manageable condition with a near-normal life expectancy
[9–11].
Observational research has consistently shown that HAART
use is associated with marked reductions in HIV transmission in
sero-discordant couples and IDUs [12,13]. More recently, a
prospective randomized trial definitively confirmed that immedi-
ate use of HAART decreased genetically linked sexually trans-
mitted HIV infection by 96.3% among HIV sero-discordant
couples [14].
Health care in Canada is provided under the auspices of the
National Health Insurance Program, often referred to as
‘‘Medicare’’ [15]. This is designed to ensure that all residents
have reasonable and affordable access to medically necessary
hospital and physician services. Provincial and territorial govern-
ments are responsible for the management, organization and
delivery of health services for their residents. HAART is subsidized
across Canada, however the nature and extent of the subsidy
varies across the country. HAART is free in British Columbia,
while in Quebec and Ontario it is covered by either public or
private insurance through a series of programs, and access may
vary according to socioeconomic status [16].
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In this study, we aimed to characterize changes in regional
patterns for new HIV diagnoses, HAART use, mortality and
averted cases in selected Canadian provinces over the past two
decades.
Methods
A population-based approach was used to characterize annual
trends new HIV-positive diagnoses, HIV-related mortality, and
HAART use in Canada from 1995 to 2008 [17]. Our analysis first
focused on all Canada, then the three provinces with the largest
epidemic and then the health authorities in British Columbia.
Below we describe how these data were collected from published
sources (also see Table 1) and how the collected data were then
analyzed.
Data sources
The numbers of new HIV-positive cases by province and health
authority in British Columbia were obtained from the latest
available reports produced by Health Canada [2] and British
Columbia Centre for Disease Control [18]. These reports
provided the number of new positive tests for each province and
territory and for the health authorities in British Columbia.
HIV/AIDS mortality data were obtained from the most
recently published reports produced by Statistics Canada [19]
and by British Columbia Vital Statistics. Deaths, in which HIV/
AIDS was reported as the underlying cause of death, were
classified according to the International Classification of Diseases
ICD, version 9, from 1987 to 1999 (codes 042–044), [20] or ICD,
version 10, from 2000 onwards (codes B20–B24) [21].
The number of people on HAART in British Columbia was
obtained from direct counts reported by the single antiretroviral
dispensing facility in the province, based at the BC-Centre for
Excellence in HIV/AIDS. The number on HAART in Ontario
and Quebec were obtained from counts of prescriptions generated
by Intercontinental Marketing Services (IMS) Health for these two
provinces. These numbers included both retail and non-retail
prescriptions. While the retail numbers were readily available, the
non-retail values had to be estimated using the number of
prescriptions in Canada and market share of non-retail drugs for
each province. It should be noted that non-retail accounts for a
negligible amount of the prescription in Quebec and Ontario.
Data on the number of HIV-positive people living in British
Columbia, Ontario and Quebec were based on estimates
produced by Health Canada [1] and by a provincial report for
Ontario [22]. Only the 2005 and 2008 values were available for
British Columbia and Quebec, the other values were interpolated
by taking into account changes in the number of new positive tests
per year.
Finally, national and provincial population figures were
obtained from annual estimates produced by Statistics Canada
[23].
Outcomes of interest
Five population health indicators were calculated for this study.
Rates of new HIV-diagnoses and deaths were calculated for all
provinces and for the health authorities in British Columbia. We
also calculated the rates of HAART coverage and averted HIV
cases and deaths for the three provinces with the largest epidemics
– British Columbia, Ontario and Quebec. All rates were expressed
per 100,000 populations.
Statistical analysis
Rates of new HIV-diagnoses and deaths were calculated by
dividing the number of cases or deaths by the total population for
that province. HIV HAART coverage was estimated by dividing
the number of people on HAART in a province by the number of
people estimated to be HIV-positive in that jurisdiction. Averted
cases and deaths were estimated by using the pre-HAART rate for
1995 and then applying it to subsequent years to estimate the
averted cases that were due to either a decrease or increase rates of
new cases or deaths in subsequent years. Rates of averted cases
and deaths were then calculated by dividing the number of averted
cases or deaths by the total population for that province. Trends in
new diagnoses were assessed using Spearman rank correlations.
Table 1. Data sources used in this study spanning the period 1995 to 2008.
National
BC, Ontario, and,
Quebec BC only
New HIV diagnoses
Health Canada x x
BC Centre for Disease Control x
HIV-related deaths
Statistics Canada x x
BC Vital Statistics x
Number on HAART
IMS* Health x
BC Centre for Excellence in HIV/AIDS x
Number of HIV+ people
Health Canada estimates x
Ontario estimates x
Population counts
Statistics Canada x
*IMS refers to Intercontinental Marketing Services.
doi:10.1371/journal.pone.0047260.t001
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95% Confidence intervals (95% CIs) were calculated for averted
HIV cases and deaths.
In order to assess the association between HAART coverage
and rate of positive tests, we used generalized estimating equations
(GEE) to solve a negative binomial regression. The GEE used an
autoregressive correlation matrix to account for the clustering of
observations within provinces, across time. An offset accounted for
the differences in provincial population sizes and the negative
binomial accounted for the over-dispersion. As we do not have
reliable data on the distribution of CD4 counts for the whole
population infected with HIV in these three provinces, HAART
coverage is based on everyone estimated to be infected rather than
only those eligible for treatment.
The BC Centre for Excellence in HIV/AIDS and the
researchers are funded by the British Columbia Government, as
well as by peer-reviewed grants and by foundations or industry
grants (see full disclosure statement). The funding sources had no
role in the choice of methods, the contents or form of this work, or
the decision to submit the results for publication. The Centre’s
HIV/AIDS Drug Treatment program has received ethical
approval from the University of British Columbia Ethics Review
Committee at its St. Paul’s Hospital site. The program also
conforms with the province’s Freedom of Information and
Protection of Privacy Act.
Results
In 2008, there were an estimated 65,000 people living with HIV
in Canada, with 55,947 (86.1%) residing in the provinces of
Ontario, Quebec and British Columbia (see Table 2). A total of
5,141, 8,753, and 6,587 individuals were on HAART in these
three provinces, respectively; with highest rate of HAART
coverage being in British Columbia at 45%, followed by Quebec
at 37% and Ontario at 32% in 2008. If 1995 rates applied Quebec
and British Columbia had the highest rates of averted deaths,
followed by Ontario.
Figure 1 highlights temporal changes in rates of new HIV
diagnoses (Panel A) 1995 to 2008 and in rates of HIV-related
mortality (Panel B) from 1995 to 2008. A total of 34,502 new HIV
diagnoses occurred in Canada from 1995–2008. Over the study
period, British Columbia was the only province with a statistically
significant decrease in new HIV diagnoses from 18.05 to 7.94 per
100,000 population (p,0.001). New HIV diagnoses per year
remained essentially constant for all other provinces except for the
Prairies, where rates increased four fold (driven by new infections
in the province of Saskatchewan). A total of 8,546 HIV-related
deaths were reported by Statistics Canada for the years 1995–
2008. Although, rates of mortality decreased in all provinces and
regions, the highest rate of decline was in Quebec with 7-fold
decrease over the study period. Rates in Ontario and British
Columbia also decreased 6 and 4-fold respectively.
The estimated number of HIV infected individuals on HAART
and the rate of HAART coverage for the provinces of Ontario,
Quebec and British Columbia, from 1995 to 2008 are shown in
Figure 2 (Panels A and B). Based on IMS Health figures for
Quebec and Ontario and direct counts for British Columbia, we
observed significant increases in HAART use in all three provinces
over the study period. Prior to 1996 only a small group of people
were on HAART as part of a prospective clinical trial in BC [24].
From 1996 to 2009, the number of HIV infected individuals on
HAART increased from 914 to 8,753 in Ontario, 295 to 6,587 in
Quebec and 2,419 to 5,625 in British Columbia. HAART
coverage was highest in British Columbia, followed then by
Quebec and Ontario.
The results of the negative binomial regression showed that the
rate of new HIV diagnoses decreased by 8% (95% CI: 2.4%,
13.3%) for each increase of 10% in HAART coverage. Figure 3
(Panels A and B) highlights number and rates of averted HIV cases
for the provinces of British Columba, 1995–2008. British
Columbia has averted more cases of HIV than Quebec and
Ontario combined. In 2008, British Columbia averted 10.33 cases
Table 2. Characteristics of those infected with HIV in British Columbia, Ontario and Quebec, 2008.
British Columbia Ontario Quebec
HIV-positive
Mid-point estimate 11,400 26,627 17,920
HIV-related deaths
Number 89 137 94
Rate per 100,000 2.03 1.06 1.21
HIV diagnoses
Number 348 1,121 638
Rate per 100,000 7.94 8.67 8.23
On HAART
Estimated number 5,141 8,753 6,587
Rate per 100,000 117.27 59,61 70.88
HAART coverage (%) 45.10 32.87 36.76
Averted HIV cases
Estimated number 348 (312, 387) 1,121(1056,1189) 638 (589, 689)
Rate per 100,000 7.94 (7.12, 8.83) 8.67 (8.17,9.19) 8.23 (7.60, 8.89)
Averted HIV-related deaths
Estimated number 257(227, 290) 669(619, 722) 532(488, 579)
Rate per 100,000 5.87(5.18, 6.62) 5.17(4.79, 5.58) 6.87(6.30, 7.47)
doi:10.1371/journal.pone.0047260.t002
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per 100,000 population (95% CI: 9.39, 11.34) compared to 3.40
(95% CI: 3.09, 3.73) and 0.33 (95% CI: 0.22, 0.49) averted cases
per 100,0000 population for Ontario and Quebec respectively.
Figure 4 (Panels A and B) highlights number and rates of
averted HIV deaths for the provinces of British Columba, Ontario
and Quebec 1995–2008. In 2008, the rate of averted deaths was
5.87 per 100,000 population (95% CI: 5.18, 6.62) in British
Columbia compared to 5.17 (95% CI: 4.79, 5.58) and 6.87 (95%
CI: 6.30, 7.47) averted deaths per 100,000 population for Ontario
and Quebec respectively.
Figure 5 (Panels A and B) highlights rates of new HIV-related
diagnoses and deaths in British Columbia for the years 1995 to
2008. The cumulative number of new HIV diagnoses in the
province was 6,374 over the study period. Rates of new HIV
diagnoses decreased significantly in all health authorities but most
notably in the Vancouver Coastal Health Authority. Over the
Figure 1. Rates of new HIV-related diagnoses and deaths in Canada. Panel A: New HIV-positive cases, by region, 1995–2008. Panel B: HIV-
related deaths, by region, 1995–2008.
doi:10.1371/journal.pone.0047260.g001
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study period, a total of 1,956 HIV-related deaths were observed.
The largest decline in rates of new diagnoses and mortality was
again observed in the Vancouver Coastal Health Authority.
Interpretation
Our results demonstrate that for each 10% incremental increase
in HAART coverage in the provinces of British Columbia,
Ontario, and Quebec, the rate of new HIV diagnoses decreased by
8% (95% CI: 2.4%, 13.3%). British Columbia stands alone in
Canada, as the only jurisdiction showing a steady decline in the
rate of HIV new diagnoses. These disparities maybe at least
partially attributed to the greater expansion of HAART coverage
in British Columbia, especially in the Vancouver Coastal Health
Authority [25], as well as the implementation of other HIV
prevention interventions, including novel harm reduction strate-
gies aimed at IDUs [26,27].
Figure 2. HAART use in British Columbia, Ontario and Quebec, 1995–2008. Panel A: Number of HIV infected individuals on HAART. Panel
B: Percent HAART coverage.
doi:10.1371/journal.pone.0047260.g002
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Rates of mortality have also decrease sharply, particularly in
Quebec and to a lesser extent in Ontario. Rates of mortality have
declined less in BC. To what extent this is a true phenomenon or is
due to an ascertainment bias remains to be established. The latter
could be due to enhanced data capture regarding mortality in BC
with regular linkages with Vital Statistics enhanced by direct
physician reporting to the centralized BC-CfE program.
Since the advent of HAART, HIV-positive individuals accessing
treatment have seen a substantial reduction in HIV-related
morbidity and mortality [28,29]. The life expectancy of HIV-
positive individuals on therapy now approaches that of uninfected
individuals, transitioning HIV from a fatal disease to a manage-
able chronic condition [11,30]. Further, a large body of global
research suggests that widespread access to HAART plays an
Figure 3. Averted HIV cases in British Columbia, Ontario and Quebec, 1995 to 2008. Panel A: Number of averted cases per year with 95%
CIs. Panel B: The rate of averted cases per year with 95% CIs.
doi:10.1371/journal.pone.0047260.g003
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important role in reducing HIV incidence at the population level.
The concept of ‘‘HIV Treatment as Prevention’’ is founded on the
basis that HAART lowers the amount of virus in the body and can
thus reduce the chance of treated individuals spreading HIV.
HAART has shown to predictably prevent vertical and percuta-
neous HIV transmission [31], and to curb sexual transmission
between sero-discordant couples [12,13]. Increased HAART
access has been associated with reduced HIV incidence by
approximately 50% in Taiwan [32], 60% in San Francisco [33]
and 60% in British Columbia [17]. Most recently, HPTN 052 – a
randomized trial of HIV sero-discordant (primarily heterosexual)
couples – provided definitive proof of the efficacy of HIV
Treatment as Prevention [14]. The study reported a 96% decrease
in the risk of sexual transmission of HIV with immediate HAART
in this setting. Of note, immediate HAART was also associated
with a 41% decrease in the combined endpoint of disease
Figure 4. Averted HIV deaths in British Columbia, Ontario and Quebec, 1995–2008. Panel A: Number of averted deaths per year with 95%
CIs. Panel B: The rate of averted deaths per year with 95% CIs.
doi:10.1371/journal.pone.0047260.g004
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progression and death, as well as an 83% reduction in the
incidence of extra-pulmonary TB. Consequently, it has been
argued that rapid expansion of HAART coverage should be
considered a clinical and human rights priority as a means to
improve HIV-related quality of life and survival, and to reduce
HIV incidence and eventually HIV prevalence [25]. Vital statistics
reports indicate that HIV/AIDS-related mortality have steadily
decreased in Canada since 1995, as a result of the increased access
to HAART [19]. However, our results show that HIV/AIDS-
related mortality rates were consistently above the national
average in some provinces. This relates to the fact that the HIV
is not randomly distributed within the population, but rather is
overrepresented within certain groups, which are expected to have
higher rates of mortality, such as injection drug users and First
Nations individuals in British Columbia [2]. Lack of access to
health care services and limited uptake of HAART within these
Figure 5. Rates of new HIV-related diagnoses and deaths in BC. Panel A: New HIV-positive cases, by health authority, 1995–2008. Panel B:
HIV-related deaths, by health authority, 1995–2008.
doi:10.1371/journal.pone.0047260.g005
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populations [34] have previously been shown to be important
drivers of excess HIV/AIDS-related mortality in Canada, despite
the existence of a socialized medical system nationally [16].
Readers should be cautious when interpreting our results. New
HIV-diagnoses are not equivalent to incident infections, as they
may have occurred over a variable period of time before the first
positive test was obtained. Therefore, true incidence cannot be
calculated due to impact of delayed and undiagnosed HIV
infections, which Health Canada estimates may reach 26 per cent
of cases [35]. HIV/AIDS-related mortality rates are underesti-
mated, as problems of misdiagnosis and underreporting are also
common, particularly with respect to the reporting of the
underlying causes of death. We have previously shown that
physician reporting underestimates HIV/AIDS-related mortality
by up to 40% [36] and that a large proportion of HIV-positive
men and women on HAART no longer die directly of HIV-
related complications [37]. As such, the figures presented in this
study may significantly underestimate the impact on HIV/AIDS-
related mortality rates. Readers should also note, while the
number of individuals on HAART in British Columbia was
derived from the single antiretroviral drug repository, the same
number for Ontario and Quebec was based on IMS Health data,
which may not be equally accurate, as it reflects drug distributed
rather than patients on therapy. Finally, estimates of HAART
coverage are based on those infected in the province rather those
that are eligible for treatment, as we do not have accuracy
estimates of CD4 distributions in these provinces over time.
Conclusions
We demonstrated that for each 10% increase in HAART
coverage in three provinces with the largest epidemic the rate of
new HIV diagnoses decreased by 8% (95% CI: 2.4%, 13.3%).
Except for British Columbia, the number of new HIV diagnoses
per year has remained relatively stable across Canada over the
study period. We believe this decline in number of new infections
may be at least partially attributed to the greater expansion of
HAART coverage, which is consistent with the recent data in
support of ‘‘HIV Treatment as Prevention’’ [25].
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